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Overall, the utility was higher for the PFS state than for baseline, but decreased below 
baseline in nonresponse and disease progression states. AEs had an important impact 
on utility within the PFS response state. The severe infection AE appeared to have a 
greater impact on patients responding to treatment compared to nonresponders, which 
may be related to the quality of life which is already low for the latter.
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OBJECTIVES: To estimate utility values associated with CML-CP health states among 
members of the general public in the UK. METHODS: Interviewer-administered time 
trade-off utilities were elicited for four CML-CP health states related to risk of progres-
sion, from a random sample of 241 members of the general public from eight cities 
across the UK, using health-state descriptions validated by clinicians and members of 
the general public. Mean utility values with 95% conﬁ dence intervals (CI) were cal-
culated for each health state. RESULTS: The respondents’ mean age was 45 years and 
51% were female. Seven percent (n = 18) of respondents had a cancer at the time of 
the interview which had been diagnosed for a mean 7.0 ± 6.5 years. The mean utilities 
with 95% CI were: 0.72 (0.69; 0.75) for untreated chronic phase CML, 0.80 (0.79; 
0.82) for hematologic response, 0.89 (0.87; 0.90) for cytogenetic response, and 0.94 
(0.94; 0.95) for molecular response. The utility values for each state are signiﬁ cantly 
different from one another (P < 0.001). The respondents’ preference values for any of 
the states were not signiﬁ cantly affected by their demographics or whether they had 
cancer. Nevertheless, the values elicited from respondents with cancer were lower than 
those elicited from respondents who did not have cancer: 0.65 versus 0.73 for chronic 
phase CML; 0.72 versus 0.81 for hematologic response; 0.83 versus 0.89 for cytoge-
netic response; and 0.89 versus 0.95 for molecular response. CONCLUSIONS: The 
health states with poorer outcome (e.g., hematologic response) were associated with 
a lower preference value than the state with the best outcome (i.e., molecular 
response). The data demonstrate the impact that different treatment responses may 
have on the health-related quality of life of patients with chronic phase CML and can 
be used to estimate the outcomes of interventions in terms of quality-adjusted 
life-years.
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COMPARISON OF EQ-5D SCORE BETWEEN TREATMENT WITH 4 
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OBJECTIVES: We investigated the effect of adjuvant chemotherapy regimens on 
utility scores assessed by the EQ-5D instrument in a randomized controlled trial for 
breast cancer patients after surgery. METHODS: In the National Surgical Adjuvant 
Study of Breast Cancer-02 (N-SAS BC 02), 1060 patients were randomly assigned 
to the following four chemotherapy groups: 1) four cycles of anthracycline (ADM 
60 mg/m2 or EPR 75 mg/m2 + CPM 600 mg/m2, q3 wks x 4) followed by paclitaxel 
(175 mg/m2, q3 wks x 4) (ACP); 2) four cycles of anthracycline followed by docetaxel 
(75 mg/m2 q3, wks x 4) (ACD); 3) eight cycles of paclitaxel (175 mg/m2, q3 wks x 8) 
(PTX); and 4) eight cycles of docetaxel (75 mg/m2, q3 wks x 8). The ﬁ rst consecutively 
registered 300 women were the subjects of the present utility study. Utility scores were 
assessed using the EQ-5D instrument at baseline, 3rd cycle, 5th cycle, 7th cycle, 7 
months, and 1 year. The obtained data were analyzed using a linear mixed model with 
baseline, time, group, and interaction between time and group as explanatory vari-
ables. RESULTS: Missing data was observed between 1.9 and 6.1% of cases depend-
ing on the time of measurement. The utility score was signiﬁ cantly lower in the DTX 
group than in the ACP and ACD groups. In the DTX group, the mean utility score 
was lowest at 7 months, and it tended to remain low for a long time. In a comparison 
of the anthracycline and taxane groups, the anthracycline group had signiﬁ cantly 
higher utility scores. There were no signiﬁ cant differences depending on the type of 
taxane. The estimated mean utility scores were 0.81, 0.83, 0.79, and 0.76 (ACP, ACD, 
PTX, and DTX group). CONCLUSIONS: The results of this study will be beneﬁ cial 
not only for clinical decision-making but also for appropriate allocation of medical 
resources.
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OBJECTIVES: Survival and quality of life (utility) are often the main measure of 
beneﬁ t used in an economic evaluation. Additionally, some decision-makers will 
consider beneﬁ ts in terms of work productivity. The present study was designed to 
estimate utilities and productivity loss for women with metastatic breast cancer (MBC) 
which is Human Epidermal Growth Factor Receptor 2 positive (HER 2+). METHODS: 
Health-state vignettes describing MBC progressive disease, stable disease, and seven 
grade 3/4 adverse events (diarrhea, fatigue, anemia, leukopenia, anorexia, decreases 
in left ventricular ejection fraction [LVEF], and skin rash) were developed based on 
interviews with women with MBC in the The Netherlands and Sweden and clinicians. 
a general public sample rated the states (100 men and women in NL; 100 women 
aged 50+ in Sweden) using the time trade off method. Women (161 The Netherlands, 
52 Sweden) who were currently or recently treated for MBC were surveyed using the 
Work Productivity and Activity Impairment scale regarding the impact of disease on 
their ability to work. RESULTS: MBC progressive disease and stable disease were 
rated more highly in Sweden (0.61, 0.81) than the The Netherlands (0.50, 0.69). 
Utilities for toxicities ranged from 0.52 to 0.69 (Sweden), and 0.47 to 0.66 (NL). The 
productivity survey identiﬁ ed that women currently receiving treatment reported that 
their overall productivity was reduced by 69% (NL) and 72% (Sweden); while those 
who had recently completed therapy reported reductions of 41% (NL) and 40% 
(Sweden). CONCLUSIONS: This study captured utility and productivity data for the 
The Netherlands and Sweden regarding the impact of HER 2+ MBC. Important dif-
ferences in utilities emerged in the study which could impact cost-effectiveness esti-
mates. The productivity survey demonstrated how the negative impact of breast cancer 
on productivity persists after women have completed their treatment.
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OBJECTIVES: Previous studies in cancer patients have found scores of ≥5 on 11-point 
pain scales to indicate pain that has a signiﬁ cant impact on patients’ lives. This study 
sought to conﬁ rm the adequacy of a ≥5 cutpoint on the BPI-SF “worst pain” item for 
deﬁ ning pain progression in CRPC patients using data collected as part of a multina-
tional phase III clinical trial. METHODS: Patients with a BPI-SF worst pain score ≥5 
were compared with patients with a score <5 in terms of Functional Assessment of 
Cancer Therapy—Prostate (FACT-P) subscales and total score and EQ-5D item scores. 
Exploratory analyses were also conducted to investigate any potential differences 
within designated regional subgroups of patients. All analyses were performed using 
treatment-blinded data collected at the ﬁ rst post-baseline trial visit including the above 
assessments (Week 12). RESULTS: A total of 464 patients completed the BPI-SF at 
W12 (<5 n = 411, ≥5 n = 53). Mean FACT-P total scores for patients with a BPI-SF 
worst pain score ≥5 were 24.5 points lower than for patients with a score <5 (91.1 
vs. 115.6, P < 0.0001), indicating poorer well-being. Patients with BPI-SF worst pain 
scores ≥5 consistently had lower scores for all FACT-P subscales (P < 0.0001) except 
for social well-being. The magnitude of these differences, for all scales, was consider-
ably greater than reported thresholds for meaningful difference. Results for EQ-5D 
item scores were in a similar direction with signiﬁ cantly greater impairment reported 
in patients with a BPI-SF worst pain score ≥5 compared with patients with a score <5 
(P < 0.0001). Exploratory analyses also revealed similar results across all regional 
subgroups of patients. CONCLUSIONS: Patient scores ≥5 on the BPI-SF “worst pain” 
item are associated with signiﬁ cant and meaningful impairments in CRPC patients, 
thus supporting the adequacy of this cutpoint as an appropriate deﬁ nition of pain 
progression in this population.
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OBJECTIVES: The standard lexicon for reporting adverse events in National Cancer 
Institute (NCI) sponsored clinical trials is the Common Terminology Criteria for 
Adverse Events (CTCAE), which consists of 790 individual items. Currently, all 
adverse events are reported by clinicians. However, multiple studies have found that 
clinicians tend to underreport symptom severity and onset compared with patient 
self-reports. In 2008, the NCI contracted a multi-institution consortium to develop 
patient versions of CTCAE items and an electronic platform for capturing symptoms 
from patients and reporting data to health care providers and researchers. METHODS: 
A committee including clinical investigators, methodologists, patients, and representa-
tives of NCI and FDA systematically identiﬁ ed CTCAE items with a subjective com-
ponent amenable to patient reporting. Systematic review and analyses of publications 
and existing symptom survey data sets and questionnaires were conducted to deter-
mine optimal formats for questions, response options, and terms for new PRO-CTCAE 
items. RESULTS: 81 symptoms were identiﬁ ed in the CTCAE to be amenable to 
patient reporting. The format and content of these items were found to be inappropri-
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ate for patient reporting in their current form, due to mixing of symptom attributes 
within items and technical jargon. The committee determined that measured attributes 
for each symptom should include frequency, severity, and activity interference. Ques-
tions and response options were standardized, along with plain language terms for 
each symptom. a web-based platform was developed for administering the new PRO-
CTCAE items. CONCLUSIONS: In response to a charge from the NCI, the PRO-
CTCAE, a patient version of the CTCAE system, has been developed. The prototype 
is undergoing testing to assess validity, usability, and logistical feasibility in a variety 
of cancer care settings. The PRO-CTCAE system has the potential to enhance adverse 
event reporting by integrating patient experiences and can foster consistency of data 
collection methods across studies.
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DEVELOPMENT OF A COMPUTER-ADAPTIVE PATIENT REPORTED 
OUTCOME TOOL FOR THE SCREENING FOR PSYCHO-ONCOLOGICAL 
TREATMENT NEEDS
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OBJECTIVES: Diagnosis and treatment of cancer entail a considerable amount of 
distress which in a large percentage of patients would require psychooncological treat-
ment (POT). There is though a lack of precise and economic measures for assessing 
the need for POT. Its detection in clinical routine often depends on procedural and 
personnel conditions. The aim of the study was the development and implementation 
of a patient-reported outcome tool for the screening of distress. a further aim is the 
construction of a computer-adpative testing (CAT) version. METHODS: 115 breast 
cancer outpatients attending the Department of Gynaecology at Innsbruck Medical 
University were consecutively included in a pilot study. Logistic regression analysis 
and ROC analyses identiﬁ ed the most predictive items from a set of questionnaires 
(EORTC-QLQ-C30, HADS, and Hornheide Screening Instrument) and other addi-
tional questions. The development of the CAT screening tool comprises generating an 
item bank, developing the CAT-algorithm and applying and implementing the CAT 
in clinical practice. RESULTS: Data from 105 breast cancer patients (mean age 58.8, 
SD 12.3) were analyzed. The EORTC QLQ-C30 scales Emotional Functioning and 
Role Functioning as well as the yes–no question after psychiatric/psychological/psy-
chotherapeutic treatment at any point in lifetime showed high predictive power with 
regard to need for POT (AUC = 0.88; CI 95% 0.82–0.95). The generation of the item 
bank resulted in 52 prelinimary items which will be subjected to further analyses. 
CONCLUSIONS: The implementation of precise and effective measures for POT 
needs is essential for providing comprehensive and high-quality cancer care. CAT 
methodology contributes to the reduction of patient burden and assessment duration, 
and increases efﬁ ciency as well as measurement precision.
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OBJECTIVES: Computer-adaptive testing (CAT) is an advanced method for measur-
ing patient-reported outcomes. With help of an algorithm, CAT selects the items most 
relevant for an individual patient from an item bank. Our study aim was the develop-
ment of a CAT version of the EORTC QLQ-C30 Fatigue scale, its implementation in 
a software package, and its use in daily clinical routine. METHODS: Our project is 
part of a large project on CAT development conducted by the EORTC Quality of Life 
Group. To set up an initial English fatigue item list, an extensive literature research 
was performed. These items were reﬁ ned through multistage expert reviews, translated 
to German, Danish, Spanish, French, and Dutch, and ﬁ lled in by a pilot patient sample 
to collect feedback. In a next step, a large patient sample is recruited for all language 
versions to gain data for development of the item bank and the CAT algorithm. 
RESULTS: Literature research resulted in 588 fatigue items, from which 44 were 
selected after comprehensive expert reviews. Based on feedback from 52 oncological 
patients, wording and translation of several items were revised. Data have been col-
lected from about 1200 patients. Preliminary results of the CAT-analysis will be 
presented. CONCLUSIONS: By generating individually tailored item sets, CAT 
reduces patient burden and assessment duration, and increases measurement precision. 
In addition, electronic data capture increases data quality and reduces the amount of 
human resources required for data collection.
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OBJECTIVES: To compare the economic and patient-reported outcomes between 
outpatient home-based and inpatient hospital-based chemotherapy in advanced 
colorectal cancer patients. METHODS: A total of 80 patients from Severance Hospital 
in Seoul, Korea, who had stage III colorectal cancer and underwent home-based (n = 
40) or hospital-based chemotherapy (n = 40) with a FOLFOX regimen between 
January 2007 and April 2008 were enrolled. Patient satisfaction data were collected 
by a self-administered questionnaire survey. Based on hospital charge records, average 
cost (in 2008 Korean won) per chemotherapy session was estimated and compared 
between home- and hospital-based chemotherapy from a societal perspective. 
RESULTS: Patients receiving chemotherapy at home showed higher satisfaction with 
their treatment (mean satisfaction score: 3.58 ± 0.15, 5-point Likert-type scale, with 
a higher score indicating higher satisfaction) than did those treated at the hospital 
(3.23 ± 0.21; P < 0.01). After adjusting for differences in baseline characteristics 
between the two groups using multivariate analysis, those receiving home-based che-
motherapy still showed signiﬁ cantly higher satisfaction than those undergoing hospi-
tal-based therapy (β = 0.271, P < 0.001). Additionally, home-based therapy reduced 
the cost per chemotherapy session by 16.6%, compared with hospital-based treatment 
(1,694,216 vs. 2,030,383 Korean won [KW], 1200 KW ≈ 1 US dollar). The largest 
cost reduction was attributable to medical costs (−201,122 KW), followed by care-
giver’s opportunity costs (−135,000 KW). CONCLUSIONS: Higher satisfaction and 
lower economic cost for home-based chemotherapy suggests that home-based chemo-
therapy could be a popular and cost-effective treatment option for colorectal cancer 
patients who are eligible for home-based chemotherapy.
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REVIEW OF PATIENT-REPORTED OUTCOMES IN PHASE II ONCOLOGY 
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OBJECTIVES: Patients’ own assessment of the impact of anticancer therapy has been 
considered important from a patient, physician, payor, and regulatory perspective. 
Approximately 12% of all oncology clinical trials list at least one patient-reported 
outcome (PRO) measure; 50% of these are phase II trials. Use and publication of PROs 
results were systematically reviewed for breast, colorectal, ovarian, and non-small cell 
lung cancer (NSCLC). METHODS: Citeline’s TrialTrove database was searched for 
oncology trials that included PROs and were planned, ongoing or completed as of 
October 2009. Speciﬁ c trial factors examined include phase, disease type, location, 
sponsorship, type of PRO instrument(s), and publication of PRO endpoint results. 
RESULTS: Of the 5483 phase II trials retrieved for breast, colorectal, ovarian, and 
NSCLC, 9% listed PROs. PRO measures were more frequently included in NSCLC 
(13%) and ovarian cancer (10%) than in breast (7%) or colorectal (8%) cancer phase 
II trials. Fifty-two percent of these trials were sponsored by industry, with 25% and 
19% being sponsored by academic and cooperative groups, respectively. One-third of 
the trials were conducted in the United States only. PROs were most frequently measured 
with the EORTC and FACT series of questionnaires. Phase II PRO results were pub-
lished 24%, 36% and 39% of the time for breast, ovarian, and NSCLC, respectively, 
and only 18% of the time for colorectal cancer. This compares with an overall publica-
tion frequency for PRO trials (any end points) of 58% to 67% which was highest in 
NSCLC. PRO results were published more frequently for trials conducted in Asia or 
Europe. However, trial sponsorship did not impact publication frequency. CONCLU-
SIONS: PROs are infrequently assessed in phase II cancer trials. PRO measures were 
most frequently included in NSCLC trials and sponsored by industry. PRO results were 
published less frequently than other end points in these trials. Publication frequency 
differed by tumor type and trial location.
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OBJECTIVES: The aim of this study was to determine the smallest changes in health-
related quality-of-life (HRQOL) scores in the European Organization for Research 
and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) and the 
EORTC Brain Cancer Module (QLQ-BN20), which could be considered as clinically 
meaningful in brain cancer patients. METHODS: World Health Organization (WHO) 
performance status (PS) and the Mini Mental State Examination (MMSE) were used 
as clinical anchors appropriate to related subscales to determine minimal clinically 
important differences (MCID) in HRQOL change scores (range 0–100) in the EORTC 
QLQ-C30 and QLQ-BN20. a threshold of 0.2SD (small effect) was used to exclude 
anchor-based MCID estimates considered too small to inform interpretation. 
RESULTS: Based on WHO PS, our ﬁ ndings support the following integer estimates 
of the MCID for improvement and deterioration, respectively: physical functioning 
(6, 9), role functioning (14, 12), cognitive functioning (8, 8), global health status (7, 
4*), fatigue (12, 9), and motor dysfunction (4*, 5). Anchoring with MMSE, cognitive 
